Haiyi Jiang

21.2k citations
53 papers · 10.0k · 4 hit papers · h-index 25

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
  • Oncology top 0.2%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers

Papers in

    • Lung Cancer Research Studies 24
    • Peptidase Inhibition and Analysis 7
    • Colorectal Cancer Treatments and Studies 4
    • Cancer Immunotherapy and Biomarkers 3
    • HER2/EGFR in Cancer Research 3
    • Lung Cancer Treatments and Mutations 23

Haiyi Jiang

52 papers receiving 9.8k citations

Haiyi Jiang's Hit Papers

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial 2015 · 314 citations
3140+6+12Years since publication2.0k4.0k6.0k

Peers

Haiyi Jiang
Comparison fields: 5 of 102
  • Pulmonary and Respiratory Medicine 7.0k
  • Oncology 4.3k
  • Cancer Research 1.4k
  • Molecular Biology 1.8k
  • Pathology and Forensic Medicine 315
Replace Patrapim Sunpaweravong with:
Patrapim Sunpaweravong Thailand
Claire Watkins United Kingdom
Emma Duffield United Kingdom
Jin-Ji Yang China
Yukito Ichinose Japan
Daniel de Castro Spain
José Rodrigues Pereira Brazil
Benjamin Margono Indonesia
Alison Armour United Kingdom
Paul Bycott United States
Haiyi Jiang relative to Patrapim Sunpaweravong Thailand Patrapim Sunpaweravong's profile →
Citations per field
00.5×1.5×
Patrapim Sunpaweravong · 1×
Citations per year

Countries citing papers authored by Haiyi Jiang

Since Specialization
Citations

This map shows the geographic impact of Haiyi Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiyi Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiyi Jiang more than expected).

Fields of papers citing papers by Haiyi Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiyi Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiyi Jiang. The network helps show where Haiyi Jiang may publish in the future.

Co-authors

The 25 scholars most cited alongside Haiyi Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Haiyi Jiang Line = papers co-authored together Haiyi Jiang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Hit paper breakdown →
20096400
2
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Hit paper breakdown →
20111189
3
Interstitial Lung Disease in Japanese Patients with Lung Cancer
Hit paper breakdown →
2008368
4
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Hit paper breakdown →
2015314
5 2008310
6 2011174
7 2006116
8 2016112
9 2016101
10 201678
11 200477
12 200876
13 200664
14 200861
15 201947
16 201939
17 201238
18 201637
19 202034
20 202034

About Haiyi Jiang

Haiyi Jiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Epidemiology and Radiology, Nuclear Medicine and Imaging, having authored 53 papers that have together received 10.0k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (24 papers), Lung Cancer Treatments and Mutations (23 papers), Cancer therapeutics and mechanisms (10 papers), Neuroendocrine Tumor Research Advances (7 papers), Peptidase Inhibition and Analysis (7 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.0k citations), Oncology (4.3k citations), Cancer Research (1.4k citations), Molecular Biology (1.8k citations) and Pathology and Forensic Medicine (315 citations). Haiyi Jiang has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Masahiro Fukuoka, Nagahiro Saijo, Tony Mok, Alison Armour, Yi‐Long Wu, Emma Duffield, Patrapim Sunpaweravong, Sumitra Thongprasert, Yukito Ichinose and Yutaka Nishiwaki. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact